Priothera
PrivateLast Round
Series B
Feb 3, 2026
Total Funding Raised
$98.27M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Priothera is a biotechnology company that develops S1P receptor modulators to improve outcomes for patients with hematological malignancies undergoing allogeneic hematopoietic stem cell transplantation.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Priothera Comparables
Compare Priothera with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Bristol Myers Squibb | 69% | |
| MaaT Pharma | 68% | |
| Incyte Corporation | 67% | |
Priothera Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Feb 3, 2026 | ||||
| Grant | Jul 11, 2025 | ||||
| Grant | Jun 24, 2024 | ||||
| Debt | Apr 4, 2022 | ||||
| Debt | Feb 23, 2022 | ||||
Series A | Oct 12, 2020 |
Priothera Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| 4see ventures | Series B |
| Fountain Healthcare Partners | Series B, Series A |
| HealthCap | Series B, Series A |
| European Investment Bank Group | Debt |
| Tekla Capital Management | Series A |
| Earlybird Venture Capital | Series B, Series A |
| European Union | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 26, 2026
Monthly visitors increased 35% MoM.
- Feb 3, 2026
$39M round led by 4see ventures
Priothera Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Priothera's valuation, stock price, and market status.